Jaume Alijotas Reig Instituciones de las que forman parte Jefe de grupo Enfermedades Sistémicas Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Instituciones de las que forman parte Jefe de grupo Enfermedades Sistémicas Vall Hebron Institut de Recerca
Líneas de investigación Cellular microparticles study in women with and without antiphospholipid antibodies with recurrent pregnancy loses and preeclampsia. Cellular microparticles (CMP) are released depending on the activation and/or the presence of cell apoptosis. They are capable of activating both inflammatory and coagulation pathways. It seems that levels of CMP are higher in healthy pregnant women. A working hypothesis establishes that an increase of CMP levels may be found in recurrent pregnancy loses and preeclampsia. It is thought that their thrombophilic capacity may be higher in those patients with anti-phospholipid antibodies, especially among those with lupus anticoagulant. We want to determine MPC levels in non-pregnant healthy women, pregnant women without previous abnormal obstetric events, women with recurrent pregnancy loses, and women with severe preeclampsia. We are also evaluating whether there are differences related to the presence or absence of antiphospholipid antibodies. Finally, we will also characterize the exact type of CMP (endothelial, platelet-like, leuco-monocyte, and throphoblastic). IP: Jaume Alijotas Reig Pathogenic role of cellular microparticles and anti-phospholipid/anti-cofactor antibodies in recurrent implantation failures related to In Vitro Fertilization (IVF). The prevalence of failed IVF is high or very high. Besides problems intrinsic to the technique, we know almost nothing about the possible underlying causes. Anti-phospholipid/anti-cofactor (aPL/aCF) antibodies have been associated to several obstetric complications. Nevertheless, the role that these aPL/aCF antibodies may have in failed IVF is not well defined. With this randomized study we want to understand better the use that these antibodies may have on a clinical daily basis. Along with the microparticles analysis, we could end up by finding several elements that might act as risk markers; in turn, it might even help us to fine-tune the currently used therapeutic approaches. IP: Jaume Alijotas Reig Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Proyectos GLOBE: Gestación Ligada a Obesidad y al Entorno. Estudio longitudinal multicéntrico de factores de riesgo asociados a la obesidad en el embarazo IP: - Colaboradores: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Maite Avilés García Entidad financiadora: Instituto de Salud Carlos III Financiación: 135883 Referencia: PI10/01367 Duración: 01/01/2011 - 31/12/2014 Heparina de Bajo Peso Molecular (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia: estudio multicéntrico randomizado IP: - Colaboradores: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Elisa Llurba Olivé, Josep Perapoch López Entidad financiadora: Ministerio Sanidad Financiación: 80000 Referencia: EC10-205 Duración: 01/01/2011 - 31/12/2016 Envejecimiento endotelial y sus efectos pleiotrópicos sobre procesos inflamatorios, de la respuesta inmune y angiogénesis IP: Francesc Miro Mur Colaboradores: Jaume Alijotas Reig, Simon Schwartz Navarro Entidad financiadora: Fundación Invest. Médica Mutua Madrileña Financiación: 36000 Referencia: FMMA/05/2008 Duración: 24/09/2008 - 23/09/2011 CIBER: Bioingenieria, biomateriales y nanomedicina IP: - Colaboradores: Manuel López Cano, Jaume Alijotas Reig, Francesc Miro Mur, Eloy Espín Basany Entidad financiadora: CIBER Bioing., Biomateriales y Nanomedicina , BBN Financiación: 480000 Referencia: CB06/01/0012 Duración: 01/01/2007 - 31/12/2010 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3
